Literature DB >> 12030723

Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma.

V Plaza1, J Serrano, C Picado, J Sanchis.   

Abstract

The onset of fatal and near-fatal asthma attacks can be rapid. The objective of this study was to determine the frequency and clinical characteristics of rapid-onset asthma (ROA) in patients suffering fatal and near-fatal crises. Two-hundred and twenty patients with fatal or near-fatal attacks were enrolled in a multicentre, prospective study. ROA was defined as a crisis developing in < or =2 h. Data on patient and clinical characteristics were collected, and spirometric and allergy studies were performed when the patients were in a stable condition. Forty-five attacks (20%) were ROA and 175 (80%) were slow-onset asthma (SOA). The triggers for SOA and ROA attacks were different, with the ROA group having a significantly lower rate of suspected respiratory infection (7% versus 38%), higher rates of fume/irritant inhalation (9% versus 1%) and a higher intake of nonsteroidal antiinflammatory drugs (14% versus 3%). The ROA group exhibited significantly higher rates of impaired consciousness (63% versus 44%), absence of lung sounds upon admission (68% versus 42%), fewer hours of mechanical ventilation (13 h versus 28 h) and fewer days of hospitalization (8 days versus 9.5 days) than the SOA group. The 20% frequency of rapid-onset fatal and near-fatal attacks in this study suggests that rapidly developing attacks may not be rare. These findings also support a distinct clinical profile for rapid-onset asthma marked by differences in triggers, severity of exacerbation and clinical course.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030723     DOI: 10.1183/09031936.02.00241502

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control.

Authors:  Urs Frey; Béla Suki
Journal:  Lancet       Date:  2008-09-20       Impact factor: 79.321

2.  The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children.

Authors:  Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj
Journal:  Ann Thorac Med       Date:  2019 Jan-Mar       Impact factor: 2.219

3.  [Live-threatening bronchospasm during anesthesia induction : when pure routine becomes a nightmare].

Authors:  A Rüggeberg; J Breckwoldt
Journal:  Anaesthesist       Date:  2011-09-16       Impact factor: 1.041

4.  Exercise-induced wheeze, urgent medical visits, and neighborhood asthma prevalence.

Authors:  Timothy R Mainardi; Robert B Mellins; Rachel L Miller; Luis M Acosta; Alexandra Cornell; Lori Hoepner; James W Quinn; Beizhan Yan; Steven N Chillrud; Omar E Olmedo; Frederica P Perera; Inge F Goldstein; Andrew G Rundle; Judith S Jacobson; Matthew S Perzanowski
Journal:  Pediatrics       Date:  2012-12-17       Impact factor: 7.124

5.  Where do children die from asthma? National data from 2003 to 2015.

Authors:  Anna J Chen Arroyo; Christine Pal Chee; Carlos A Camargo; N Ewen Wang
Journal:  J Allergy Clin Immunol Pract       Date:  2017-09-29

6.  Asthma mortality in Australia in the 21st century: a case series analysis.

Authors:  Dianne P Goeman; Michael J Abramson; Edwina A McCarthy; Celia M Zubrinich; Jo A Douglass
Journal:  BMJ Open       Date:  2013-05-28       Impact factor: 2.692

7.  The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children.

Authors:  Mohamed S Al-Moamary; Sami A Alhaider; Majdy M Idrees; Mohammed O Al Ghobain; Mohammed O Zeitouni; Adel S Al-Harbi; Abdullah A Yousef; Hussain Al-Matar; Hassan S Alorainy; Mohamed S Al-Hajjaj
Journal:  Ann Thorac Med       Date:  2016 Jan-Mar       Impact factor: 2.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.